2023 was a tricky 12 months to the biopharma industry, with many companies downsizing and restructuring their workforces to remain afloat. You will discover indications of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences market while in the latter Section of 2023 and have ongoing https://sites.google.com/view/bio-sites/blog